skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Fixed combination of repaglinide and metformin in the management of type 2 diabetes

Review

(2892) Views  (862) Full article downloads

Authors: Robert Moses

Published Date June 2009 Volume 2009:2 Pages 101 - 109
DOI: http://dx.doi.org/10.2147/DMSO.S4436

Robert Moses

Clinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, Australia

Abstract: Treatment to target fasting blood glucose (FBG), postprandial glucose (PPG) and HbA1c are essential in the management of type 2 diabetes to reduce the risk of vascular complications. Early combination therapy with oral agents is increasingly being seen as important to achieve this. Repaglinide, a rapid-acting insulin secretagogue, targets PPG, and metformin, an insulin sensitizer, targets FBG. Because of their complementary modes of action these therapies are frequently given as combination therapy in separate tablets. To overcome the issues with adherence to multiple tablets, repaglinide and metformin are now available in a fixed-dose combination (FDC). Repaglinide/metformin FDC is bioequivalent to each tablet given separately, suggesting that the efficacy and safety profile is similar. There is no effect of food on repaglinide when in the FDC. Repaglinide/metformin FDC is as effective in reducing HbA1c and FBG whether given twice or three times daily, with a similar safety profile. Repaglinide/metformin FDC twice daily is as effective in reducing HbA1c and FBG as rosiglitazone/metformin FDC with a similar safety profile, but unlike the rosiglitazone/metformin FDC, repaglinide/metformin FDC improves the lipid profile. Repaglinide/metformin FDC represents a new option in the pursuit of achieving glucose targets and reducing vascular risk in type 2 diabetes, with the advantage of improving adherence.

Keywords: type 2 diabetes, metformin, repaglinide, fixed-dose combination






 

Other articles by Dr Robert Moses



Readers of this article also read:

Periosteoplasty for covering gingival recessions: Clinical results
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Risk management in the treatment of type 2 diabetes with pioglitazone
Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: central plus peripheral nervous system mechanisms
Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
Clinical and behavioral factors associated with management outcome in hospitalized patients with diabetic foot ulcer
Erratum
Insulin detemir for the treatment of obese patients with type 2 diabetes
Obesity: considerations about etiology, metabolism, and the use of experimental models
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio